3B Future Health Fund — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investorsCTI Life Sciences Fund L.P.adMare BioInnovationsPanacea VentureSeventure Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.